Trials / No Longer Available
No Longer AvailableNCT03014440
Study of Cannabidiol for Drug-Resistant Epilepsies
A Phase 1/2, Safety, Tolerability, and Dose-Finding Study of Cannabidiol for Drug-Resistant Epilepsies
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eric Marsh, MD · Academic / Other
- Sex
- All
- Age
- 1 Year – 20 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. Pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. There are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. There are no well-documented studies and completely analyzed data for pediatric epileptic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabidiol |
Timeline
- First posted
- 2017-01-09
- Last updated
- 2017-04-04
Source: ClinicalTrials.gov record NCT03014440. Inclusion in this directory is not an endorsement.